Conference Program

Return to main conference page

All Times EDT

Wednesday, September 21
Wed, Sep 21, 1:15 PM - 2:30 PM
Salon FG
Innovative Bayesian Methods to Leverage the Robustness and Probability of Success in Clinical Trials

Utilization of Treatment Effect on a Surrogate Endpoint for Planning a Study to Evaluate Treatment Effect on a Final Endpoint (303672)

View Presentation

Xun Chen, Sanofi 
Meehyung Cho, Sanofi 
Gautier Paux, Sanofi 
Hui Quan, Sanofi 
*Zhixing Xu, Sanofi 

Keywords: Bivariate Bayesian analysis, posterior distribution, dynamic data borrowing, power prior, probability of success

To design a phase III study with a final endpoint and calculate the required sample size for the desired probability of success, we need a good estimate of the treatment effect on the endpoint. It is prudent to utilize all available information including the historical and phase II information of the treatment as well as external data of the other treatments. It is not uncommon that a phase II study may use a surrogate/biomarker endpoint as the primary endpoint and has no or limited data for the final endpoint. On the other hand, external information of the other studies for the other treatments on the surrogate and final endpoints may be available to establish the relationship between the treatment effects on the two endpoints. Through this relationship, making full use of the surrogate information may enhance the estimate of the treatment effect on the final endpoint. In this research, we propose a bivariate Bayesian analysis approach to comprehensively deal with the problem. A dynamic borrowing approach is considered to regulate the amount of historical data and surrogate endpoint information borrowing based on the level of consistency. A much simpler frequentist method is also discussed. Simulations are conducted to compare the performances of different approaches. An example is used to illustrate the applications of the methods.